QoL better with bladder Ca immunotherapy vs. chemo – ModernMedicine
|
QoL better with bladder Ca immunotherapy vs. chemo
ModernMedicine Chicago—Patients treated with pembrolizumab (Keytruda) as second-line therapy for advanced urothelial carcinoma (UC) following platinum-based chemotherapy maintain better health-related quality of life (HRQoL) than their counterparts receiving … |
